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In this podcast, we talk to Dr Sunil Verma about the evolution of HER2 as a therapeutic target in breast cancer, and
about how targeted therapy has revolutionized breast cancer treatment. We also discuss new agents in clinical
development and the ways in which advances in treating HER2-positive breast cancer can be used to inform
treatment decisions in other areas of medicine.
The podcast for this interview is available at: http://media.biomedcentral.com/content/movies/supplementary/
SunilVerma-QandA.mp3.
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Dr Sunil Verma (Figure 1) is a medical oncologist who is inter-
nationally recognized for his research and education leadership
in breast cancer. He is the principal investigator for many
clinical trials in breast and lung cancer, and has led pioneering
trials showing that the antibody-drug conjugate T-DM1
extends survival in women with advanced human epidermal
growth factor receptor 2 (HER2)-positive breast cancer.
In this interview, we talk to Dr Verma about how HER2
has evolved into one of the most promising targets in breast
cancer therapy, about new therapies and combinations that
are under clinical development, and how insights gained into
HER2-positive breast cancer can inform treatment decisions
across oncology.
The podcast for this interview is available at: http://
media.biomedcentral.com/content/movies/supplementary/
SunilVerma-QandA.mp3.
1. Could you tell me a bit about yourself and how you
got into working in the field of breast cancer?
I trained at the University of Alberta, which is in Edmonton,
Canada. Early on in my career I was quite amazed by the
fight, the bravery, and the courage of cancer patients. I
thought, ‘what an incredible way to battle this disease’. I, in
many ways, wanted to be part of that battle with them, and toCorrespondence: sunil.verma@sunnybrook.ca
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unless otherwise stated.be able to learn from how these patients live their lives and
how they are able to manage such a life-transforming experi-
ence. Being part of that journey was quite empowering for
them and also for the healthcare workers as well. So that’s
really what attracted me towards oncology.
Through training in oncology, I met some wonderful men-
tors along the way. One in particular is Dr John Mackey,
who is based at the Cross Cancer Institute in Edmonton.
Seeing how he worked and his expertise in breast cancer is
really what excited me to join the field. From there on, I did
a fellowship in breast cancer at Sunnybrook Cancer Center
in Toronto, and came on staff here about 10 years ago.
I now lead the breast cancer trials group here at
Sunnybrook. The research that we do is across the spectrum –
from quality of life to assessing and caring for end of life
patients. However, our main focus, and my main focus, is in
the HER2-positive arena. Of course I partake in research across
the board; we have a number of fellows and residents who work
with us, and it is a really great opportunity to conduct research
and also teach others how to do research in breast cancer.2. Thirty years after its discovery, HER2 is one of the most
promising targets in breast cancer therapy. Could you take
us through how HER2-directed treatments have developed
and how they have impacted therapy, particularly with early
breast cancer?
It is a journey 30 years in the making. The HER2 gene was
identified around 1984, and this was followed with work byhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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breast cancer patients who have HER2 overexpression and
amplification had the worst prognosis. The advent of trastuzu-
mab occurred in the early 1990s, and in the late 1990s it was
shown that the incorporation of trastuzumab with standard
chemotherapy improves overall survival. By the late 1990s, we
had this information, and by 2000 we were using it for treat-
ment of metastatic advanced HER2-positive breast cancer.
Over the past decade, I think our understanding of HER2-
positive breast cancer has transformed significantly, going
from a sense of using a targeted drug with chemotherapy –
in effect, you lose the essence of targeted treatment when
you’re giving it along with chemotherapy – to a point where
we’re now using dual targeted therapy with trastuzumab
and lapatinib, and dual targeted therapy with two antibodies
(trastuzumab and pertuzumab). Our own work has
highlighted the role of antibody-drug conjugates, moving
away from traditional chemotherapy. I say this is truly a
‘targeted treatment’, as it incorporates both targeted therapy
and targeted chemotherapy, in order to specifically target
the HER2-positive cancer cells.3. As well as their positive impact on early breast cancer,
HER2-targeted therapies have shown promise for treating
advanced breast cancer. For example, your clinical trials
showed that an antibody-drug conjugate against HER2
prolonged survival in women with metastatic disease.
Could you tell me a bit more about the impact of
HER2-directed therapies on advanced breast cancer?
The use of trastuzumab in the adjuvant setting has im-
proved overall survival, decreased the risk of recurrence
by about 50% in relative terms, and has transformed our
approach to treating breast cancer. However, we still
have some patients who develop metastatic breast can-
cer, either de novo or patients who have had prior ther-
apy and have relapsed. So, we still need to work a lot in
understanding and treating our patients with advanced
HER2-positive breast cancer.
In the past decade, we have gone from overall survival
in the range of about 25 to 30 months with chemother-
apy plus trastuzumab, to overall survival of more than
40 to 45 months with chemotherapy plus trastuzumab
and pertuzumab in the first line setting. So, there has
been a significant improvement in the first line setting.
We have also learned that continued blockade of the
HER2 receptor, either using antibodies or tyrosine kinase
inhibitors (TKIs), is important to use alongside of
chemotherapy and trastuzumab in the second line and
beyond setting. The importance of chemotherapy and
lapatinib has also been demonstrated in the second line
and beyond setting, for patients who have progressed on
trastuzumab.
I think one of the most significant advances in treating
HER2-positive advanced breast cancer has been the use of
antibody-drug conjugates. The concept of antibody-drug
conjugates has been around for more than 30 years, but
our study looking at trastuzumab emtansine, or T-DM1,
was the first trial in solid tumors to show that such a con-
cept can be harnessed to treat breast cancer patients. Not
only does T-DM1 extend survival, but it also comes with
less toxicity and fewer side effects compared with standard
treatment. In oncology, it is rare to see treatments that
lead to better outcomes and come with less toxicity. That
is why the study was so pivotal. Now, T-DM1 would be
considered standard care for patients who have progressed
after first line anti-HER2 therapy.
4. How are HER2-directed agents being evaluated for
early and advanced breast cancer?
The next focus is going to be looking at whether we can
completely forgo chemotherapy in HER2-positive breast
cancer. In our own research, we will investigate whether
we can get the true essence of total targeted treatments
through combining targeted therapies, whether it is
trastuzumab-pertuzumab, trastuzumab-lapatinib, or other
anti-HER2 partners. We will also be looking at the use of
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with other targeted drugs, and trying to see whether such
an approach can be used in advanced cancer to delay the
use of chemotherapy. Additionally, just as importantly, I
think such an approach can be used in early breast cancer,
where we can only reserve chemotherapy for a selected
number of patients and use a total targeted treatment for
most of our patients.
5. Which HER2-directed therapies are currently under
clinical development?
There are a number of agents undergoing further evalu-
ation. The three most used agents, of course, we have
talked about; above and beyond trastuzumab, there is per-
tuzumab, lapatinib and T-DM1, which are in clinical use
in most places around the world now. With respect to
what is coming next, there have been some data suggest-
ing that everolimus, an MTOR inhibitor, appears to be
very promising in patients in the second line and beyond
setting. However, in combination with chemotherapy, it
was associated with significant toxicity. Everolimus may
be of specific interest in patients who are hormone
receptor-negative HER2-positive; I think the use of evero-
limus in this setting requires further evaluation.
There is significant interest in developing the second-
generation tyrosine kinase inhibitors. One of the drugs
is neratinib, which is currently being studied in a large
Phase III trial called the NALA study, comparing nerati-
nib and capecitabine versus capecitabine and lapatinib.
Neratinib is a pan-HER inhibitor, a more potent tyrosine
kinase inhibitor. Initially, there were some concerns with
toxicity with diarrhea, but some of those concerns have
been addressed by proper incorporation of anti-diarrheal
medication with breast cancer treatment.
The next question is whether we can expand and build
on this concept of combining chemotherapy and targeted
therapy. One of the drugs that looks promising is called
MM-302, which is a combination of Her-2 targeted anti-
body and anthracyclines. MM-302 is going to be going
through Phase II and Phase III clinical trials shortly.
I think this area, by no means, has been fully under-
stood. We need to continue to work on developing bet-
ter therapies, and using the treatments that we have in a
more user-friendly, patient-friendly, and patient-focused
manner, to really harness the true strength and effective-
ness of these treatments.
6. You have described some really promising results
looking at different combinations of targeted therapies.
Do you anticipate that these combinations will be used
more routinely in the clinic in the future?
Yes, I think they will be. I think the best way to evaluate
routine use is going to be increased participation and in-
corporation in the neoadjuvant setting. I think the morewe can study these drugs in the neoadjuvant setting,
where we have tumors evaluated before the start of treat-
ment and after the completion of treatment, the better we
can understand what is happening at the patient level.
This will then help us to better understand the biology
of tumors, the biology of how these drugs work, and
the biology of resistance. I think this is where we are
moving forward.
We also have a very unique opportunity to incorporate
functional imaging along with assessment of pathology.
Also, I think it would be wonderful to be able to assess
functional diagnostics, in order to assess how these
drugs are working through imaging.
Moving forwards, another goal is to be able to identify
patients who are more likely to benefit from a total tar-
geted treatment approach. The only way we could do
that is by understanding the biomarkers of the tumor. If
we can come up with a biomarker signature that tells us
that if you have a total targeted treatment approach,
your likelihood of clinical response is close to 100%, or
your likelihood of a pathological complete response is
above 90%, then we can start asking the question of
whether we can potentially forgo surgery or radiation
treatment for some of these patients when we are having
such a significant benefit from targeted therapy.
I think we are just on the cusp of truly understanding
how to use these targeted treatments. The only way we
are going to be successful is not only by improving patient
outcomes, but also seeing whether we can use these total
targeted treatments in such a way that we can forgo
some of the traditional weapons such as chemotherapy,
radiation and surgery. I think that would be a signifi-
cant achievement in not only breast cancer but oncology
as a whole.
7. Could you tell me what your visions are for the future
of treating HER2-positive breast cancer?
My vision, exactly as we were discussing, is to be able to
offer a total targeted approach in the early breast cancer
setting, forgoing chemotherapy for most patients, and
only reserving chemotherapy for a selected few. The sec-
ond step would be using targeted treatments where we
can have a very good assessment of which patients are
most likely to benefit. This would be a more selected,
more cost-effective approach, and could have such a sig-
nificant impact that we could forgo not only chemother-
apy, but maybe surgery and radiation for some of our
patients. In the advanced stage setting, my vision for
the future is using tailored treatment based on specific
biomarkers, where we tend to use a targeted approach
initially, and use chemotherapy only at a later stage.
This, in a nutshell, summarizes the vision. In order
for this vision to come true, I think we really need every-
body on board, including industry, patient groups, patient
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see how we can work together and how we can design
trials to look at these very important questions. This
should allow us to really shift the care to a chemotherapy-
free approach and really improve the outcome of our pa-
tients and, at the same time, not introduce any significant
side effects.
8. You have outlined some tremendous progress that has
been made in treating HER2-positive breast cancer. Could
you now tell me about other targeted approaches in
solid tumors and how the results from clinical trials in
HER2-positive breast cancer can inform treatment
decisions in other cancer types?
The insights that we have gained from HER2-positive
breast cancer have been tremendous. One of the first
publications on combining chemotherapy and targeted
treatments was in 2001, with the use of trastuzumab and
chemotherapy. Then, we have the data for capecitabine
and lapatinib, one of the first times we have shown that
TKIs can be combined with chemotherapy. We also
showed that TKIs can be used in combination with an
antibody, with lapatinib and trastuzumab; this was one
of the first times in oncology that such an approach was
found to be so successful. The dual antibody approach
with pertuzumab and trastuzumab was demonstrated by
José Baselga in 2011; this was one of the first insights
that we can combine two antibodies to gain synergy by
targeting the same receptor. The antibody-drug conju-
gate concept that we published in 2012 showed that
there is a significant achievement in efficacy without the
side effects. Again, this was one of the first times in on-
cology that such an effect was shown.
These principles of combining antibodies, combining
antibodies with TKI and the antibody-drug conjugate in
HER2-positive breast cancer have taught us a lot of in-
sights that are now applicable to many other tumor
types. There is now a significant interest in combining
two antibodies in colorectal cancer; the development of
antibody-drug conjugates is now occurring across the
board in many different tumor sites. The concept of
combining an antibody and a TKI has gained significant
interest in lung cancer research, looking at combinations
of drugs like cetuximab and afatinib, showing that there
is some synergy in preliminary studies. I think the in-
sights that we have gained in how to target oncogenes in
HER2-positive breast cancer are going to be applied
across the board in many other tumor sites.
I think the model of care and the design of studies that
we are currently using will have a significant reach above
and beyond HER2-positive breast cancer. I think this
journey has just started with the identification of tar-
geted drugs and user-targeted drugs, but it still needs to
be established how best to optimize their use and reallyharness their strength; I think this will have a significant
impact above and beyond breast cancer.
9. Where can I find out more?
See reference list [1–6].
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